Organicell Regenerative Medicine, Inc., US68621D1072

Organicell Regenerative Medicine, Inc., US68621D1072

14.11.2022 - 15:20:26

EQS-News: Can This Company?s Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?

ways to derive embryonic stem cells from early mouse embryos.

That discovery was followed by a method to derive stem cells from human embryos and grow the cells in the laboratory in 1998.

Massive players like Amgen Inc. (NASDAQ: AMGN), Sanofi SA (NASDAQ: SNY), and Gilead Sciences Inc. (NASDAQ: GILD) have advanced stem cell research and therapies.

Is Exosome Therapy Different?

Unlike stem cell therapy, Organicell?s (OTCMKTS: OCEL) exosome therapy doesn't involve using donor cells or umbilical cords. Instead, the exosomes are extracted from full term, planned C Section, Amniotic fluid. The extracted exosome solution is derived from amniotic fluid and contains over 300 soluble proteins as growth factors, cytokines and chemokines, extracellular matrix proteins as fibronectin and collagen, structural molecules as hyaluronic acid, Nanoparticles as extracellular vesicles, exosomes and surfactants proteins, valuable lipids, micro-RNA, messenger-RNA, and cytokines.

Exosome therapy, according to experts, is a highly targeted, flexible treatment believed to help inflammatory conditions like COPD, Long Covid, musculoskeletal injuries, osteoarthritis, and chronic pain.

What?s the difference between Exosomes and Stem Cells?

Try to think of Stem Cells as microchips in a computer. Exosomes are like the software.

South Florida-based Organicell Regenerative Medicine Inc. (OTCMKTS: OCEL) is a company that is a pioneer in the exosome space. Their products are designed to operate like software for the computers of our body known as cells. However, the software Organicell uses is naturally occurring and unaltered. Organicell extracts its exosomes from what is believed to be one of the most naturally healing fluids on the planet, amniotic fluid. The software/exosomes in this fluid reminds the body what it used to do when it was young.

To put things plainly, the ?software? (exosomes) is a set of instructions, data or programs used to operate the ?computers? (cells) and execute specific tasks, while a computer-chip (stem cells) are used more as building blocks in regenerative medicine.

Potential Benefits

The potential benefits of Organicell?s products could be enormous. For example, the company's investigational product Zofin? is an acellular, non-HCT/P biologic, currently being studied in clinical trials. The company accomplished the difficult task of an approved investigational new drug (IND) from the U.S. Food and Drug Administration (FDA) which lead to approved clinical trials..

Zofin? is derived from perinatal sources and is manufactured to retain the naturally occurring nanoparticles and microRNAs without manipulation or adding or combining any other substance.

Zofin? is currently being studied in FDA Phase I/II clinical trials for COVID-19, Long Covid, Chronic Obstructive Pulmonary Disease (COPD), and ready to begin a trial for Osteoarthritis of the knee.

Below are the results that were published on the COVID patients treated with Zofin under eIND approval. The important items in the chart are the key biomarkers that measure inflammation: IL-6 and CRP as well as the chest X Rays that show the structural difference in the lungs over time.

A Better Approach?

Organicell reports that its mission is to be the first company to prove the efficacy of extracellular vesicles (EV's) ? a.k.a exosomes ? on inflammatory ailments. Organicell has two active FDA approved clinical trials for Long Covid and COPD.

The company says through its ground-breaking research in the field of nanotechnology, specifically perinatal-derived EVs, it has created the drug candidate, Zofin, that could be the next frontier of regenerative biologic therapeutics.

Organicell?s proprietary product?s biological representation is allogenic amniotic fluid (secreted body fluid, non-HCT/Ps), which is an acellular product derived from human amniotic fluid (HAF). The product contains no addition or combination of any other substance or diluent during production.

Moreover, the product quality assurance is seemingly unmatched in the regenerative medicine space. the donor from whom this product was derived has been tested and found negative for the following: HBsAg (Hepatitis B Surface Antigen), HBcAb (hepatitis B core antibody), HCV (hepatitis C antibody), HIV I/II-Ab (Antibody to Human Immunodeficiency Virus Types 1 and 2), Syphilis detection test, HIV NAT (HIV Nucleic Acid Test), and HCV NAT (HCV Nucleic Acid Test).

Additional donor screening tests may have been performed on the donor. If additional tests for Human Immunodeficiency Virus, Hepatitis B, Hepatitis C or Syphilis were performed, the results were reviewed and found to be NEGATIVE.

Additional tests for other communicable diseases, such as West Nile Virus, T. Cruzi, Cytomegalovirus and Epstein Barr Virus may have been performed. The results of all additional communicable disease tests have been evaluated by the Medical Director and have been found acceptable according to regulations, standards and Standard Operating Procedures (SOPs).

Donor screening tests are performed by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and American Association of Blood Banks (AABB) using FDA licensed tests when available performed by VRL Laboratories.

The donor is selected based on medical and social history which meets the Standards of the American Association of Tissue Banks (AATB) United States Public Health Service (USPHS), and the Federal Food and Drug Administration (FDA).

Donor suitability was determined by the Manufacturing Facilities? Medical Directors (Organicell Regenerative Medicine, 1951 NW 7th Ave, Suite 300, Miami, FL 33136). Organicell Factor X is manufactured for clinical use under cGMP-compliant manufacturing facility, to control potency and purity of the product.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent.

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Organicell Investor Relations

IR@organicell.com

Company Website

https://organicell.com/

News Source: News Direct

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Organicell Regenerative Medicine, Inc.

United States ISIN: US68621D1072 EQS News ID: 1487229 ? End of News EQS News Service

1487229??14.11.2022?CET/CEST

@ dgap.de